Literature DB >> 7516070

Cathepsin D cytosolic assay and immunohistochemical quantification in human prostate tumors.

M Chambon1, X Rebillard, H Rochefort, J P Brouillet, P Baldet, J Guiter, T Maudelonde.   

Abstract

We quantified cathepsin D by immunoradiometric assay (IRMA) and quantitative immunohistochemistry in fifteen human prostate cancers, seventeen BPH, and nine normal prostates. The cytosolic cathepsin D concentration was higher in prostatic carcinoma (mean: 31.5 pmol/mg cytosol proteins; range: 10.2-66.2) than in normal prostate (16.0 pmol/mg cytosol proteins; 7.2-25.5; P = 0.01). Prostatic hyperplasia showed intermediate values (20.2 pmol/mg cytosol proteins; 7.6-33.9). Immunostaining of cathepsin D and prostatic acid phosphatase on serial frozen sections of prostate tissues was only observed in glandular epithelial cells. Immunostaining was quantified by computer-assisted image analysis as an quantitative immuno-cytochemical score (QIC score) expressed in arbitrary units (A.U.). QIC scores for cathepsin D were dispersed and had a tendency to be higher in benign prostatic hyperplasia (mean: 178.3 A.U.; range: 95-297) compared to normal prostate (85.2 A.U.; 2-173 P < 0.01) and prostatic carcinoma (90.0 A.U.; 21-179 P = 0.0002). Prostatic cathepsin D levels in cytosols or immunostaining sections were independent of other clinicobiological parameters.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516070     DOI: 10.1002/pros.2990240608

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  4 in total

Review 1.  Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications.

Authors:  Gaetano Leto; Francesca M Tumminello; Marilena Crescimanno; Carla Flandina; Nicola Gebbia
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 2.  Possible role of procathepsin D in human cancer.

Authors:  A Vashishta; M Fusek; V Vetvicka
Journal:  Folia Microbiol (Praha)       Date:  2005       Impact factor: 2.629

Review 3.  Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer.

Authors:  Delisha A Stewart; Carlton R Cooper; Robert A Sikes
Journal:  Reprod Biol Endocrinol       Date:  2004-01-07       Impact factor: 5.211

4.  Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.

Authors:  Kathrin Endt; Jens Goepfert; Aurelius Omlin; Alcibiade Athanasiou; Pierre Tennstedt; Anna Guenther; Maurizio Rainisio; Daniel S Engeler; Thomas Steuber; Silke Gillessen; Thomas Joos; Ralph Schiess
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.